Cilengitide from MedChemExpress

Product Specs
ItemCilengitide
CompanyMedChemExpress
Price $171.00Supplier Page View Company Product Page
Catalog NumberHY-16141
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.80%
TypeChemical
Molecular Weight588.66
FormulaC₂₇H₄₀N₈O₇
Research AreaCancer

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Macrophage-derived legumain ameliorates excessive mechanical stress-induced ferroptosis of nucleus pulposus cells and intervertebral disc degeneration via integrin αvβ3–Hippo signalingCellular & Molecular Biology LettersMarch 23, 2026Peiyang Wang, Zhiyang Xie, Liting Deng, Yan Zhou, Zhengyuan Xu, Jiawei Gao, Rui Sun, Lei Liu, Zhiwei Wang, Xiaotao Wu, et al.indicated concentrations or cotreated with rLGMN and the integrin αvβ3 antagonist Cilengitide (MCE, HY-16141) across a defined concentration range under compression. Macrophages were then plated onto insert membranes

(2) Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK –driven lung cancer by concurrent integrin and MET signalingScience SignalingDecember 23, 2025Qianqian Hu, Lily L. Remsing Remsing Rix, Bina Desai, Daria Miroshnychenko, Xueli Li, Eric A. Welsh, Bin Fang, Gabriela M. Wright, Neelkamal Chaudhary, Jodi L. Kroeger, et al.Tween80), capmatinib (3 mg/kg, MedChemExpress, #HY-13404, oral), cilengitide (5 mg/kg, MedChemExpress, #HY-16141, i.p.), alectinib (20 mg/kg, Hoffmann-La Roche, oral), alectinib plus capmatinib, alectinib plus cilengitide

(3) Irisin regulates integrin αvβ5/FAK/ERK to inhibit neutrophil extracellular traps formation and reduce pancreatic beta-cells pyroptosis in type 2 diabetes mellitusDiabetol Metab SyndrJuly 18, 2025Anjun Tan, Tianrong Li, Jingjing Yang, Xiaolu Li, Wenqin Li, Jinwen Yupre-treated with 1 µM Defactinib (FAK inhibitor, MCE, HY-12289) or 1 µM Cilengitide (αV/β5 inhibitor, MCE, HY-16141), respectively, for 30 min, followed by 1 mM PMA stimulation for 4 h. A PBS-treated group was included

(4) Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma ProgressionInt J Biol SciMay 27, 2025Yifan Wu, Shuquan Li, Hao Yu, Sha Zhang, Liang Yan, Xiaoya Guan, Wei Xu, Zhen Wang, Ang Lv, Xiuyun Tian, et al.recombinant human Periostin (rhPOSTN, Novoprotein, CJ39), or integrin αvβ5 receptor inhibitor (MCE, HY-16141). Cells (2,000 cells/well) were seeded in 96-well plates and cultured for 5 d, with 10 μL CCK-8 (Dojindo)

(5) Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarizationOncoimmunologyMay 22, 2025Rita Caracuel-Peramos, Francisco Javier Rodríguez-Baena, Silvia Redondo-García, Juan Antonio Villatoro-García, Ana García-Muñoz, Carlos Peris-Torres, María Del Carmen Plaza-Calonge, Alba Rubio-Gayarre, Belén López-Millán, Carmela Ricciardelli, et al.macrophages.8 To investigate its role, BMDMs were pre-treated with the αvβ3 antagonist cilengitide (HY-16141, MedChemExpress) prior to polarization. This pre-treatment markedly reduced Nos2 expression induced

(6) Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarizationOncoimmunologyMay 22, 2025Rita Caracuel-Peramos, Francisco Javier Rodríguez-Baena, Silvia Redondo-García, Juan Antonio Villatoro-García, Ana García-Muñoz, Carlos Peris-Torres, María del Carmen Plaza-Calonge, Alba Rubio-Gayarre, Belén López-Millán, Carmela Ricciardelli, et al.macrophages.8 To investigate its role, BMDMs were pre-treated with the αvβ3 antagonist cilengitide (HY-16141, MedChemExpress) prior to polarization. This pre-treatment markedly reduced Nos2 expression induced

(7) Abnormal cytoskeletal remodeling but normal neuronal excitability in a mouse model of the recurrent developmental and epileptic encephalopathy-susceptibility KCNB1-p.R312H variantCommunications BiologyDecember 30, 2024Alessandro Bortolami, Elena Forzisi Kathera-Ibarra, Anastasia Balatsky, Mansi Dubey, Rusheel Amin, Srinidi Venkateswaran, Stefania Dutto, Ishan Seth, Adam Ashor, Angel Nwandiko, et al.mg Chemicals,Chemicals,Chemicals Guangxitoxin 1E,Biotechne,Cat# 5676 Cilengitide,MedChemExpress,Cat# HY-16141 PND1186,MedChemExpress,Cat# HY-13917 Latrunculin A,Thermo Fisher Scientific,Cat# L12370 Jasplakinolide,Thermo Fisher Scientific

(8) Modulating the extracellular matrix to treat wound healing defects in Ehlers-Danlos syndromeiScienceSeptember 20, 2024Kindra M. Kelly-Scumpia, Maani M. Archang, Prabhat K. Purbey, Tomohiro Yokota, Rimao Wu, Jackie McCourt, Shen Li, Rachelle H. Crosbie, Philip O. Scumpia, Arjun Debhealing (Figure S2). Treatment of animals with Cilengitide Cilengitide was purchased from (MCE, #HY-16141). Mice were given an intraperitoneal injection of Cilengitide (20mg/kg) diluted in PBS intraperitoneally

(9) Epidermal growth factor-like domain 7 drives brain lymphatic endothelial cell development through integrin αvβ3Nature CommunicationsJuly 16, 2024Jingying Chen, Jing Ding, Yongyu Li, Fujuan Feng, Yuhang Xu, Tao Wang, Jianbo He, Jing Cang, Lingfei Luointegrin α5β1 inhibitor-ATN-161(Selleck, #262438-43-7) and the integrin αvβ3 inhibitor-Cilengitide (MCE, #HY16141) stock solution of 10 mM in DMSO was used to prepare a working solution-50 μM and treat the embryos

(10) Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma modelBioengineeredFebruary 1, 2022Pan X, Yi M, Liu C, Jin Y, Liu B, Hu G, Yuan X.

(11) Irisin Suppresses Nicotine-Mediated Atherosclerosis by Attenuating Endothelial Cell Migration, Proliferation, Cell Cycle Arrest, and Cell SenescenceFrontiers in cardiovascular medicineJanuary 1, 2022Chen J, Li K, Shao J, Lai Z, Gao R, Wang C, Song X, Guo W, Yu X, Du F, et al.applied as mentioned above, n = 8; and (V) Nicotine + Irisin + Cilengitide group: 4 μg/g cilengitide (HY-16141, MedChemExpress, China) in 100 μL normal saline, intraperitoneally (i.p.), approved every other day

(12) Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsCancer cellNovember 8, 2021Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, et al.S1039 Trametinib,Selleckchem,Cat# S2673 Vactosertib,Selleckchem,Cat# S7530 Cilengitide,MedChemExpress,Cat# HY-16141 HGF,Peprotech,Cat# 100–39 FGF1,Peprotech,Cat# 100–17A FGF2,Peprotech,Cat# 100–18C FGF5,Peprotech,Cat#

(13) Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathwayAnnals of Translational MedicineMay 1, 2021Kang Li, Junye Chen, Chaonan Wang, Jiang Shao, Zhichao Lai, Xiaoxi Yu, Fenghe Du, Ran Gao, Jing Wang, Bao Liuapplied as mentioned above, n=8; and (5) Nicotine + Irisin + Cilengitide group: 4 μg/g cilengitide (HY-16141, MedChemExpress, China) in 100 μL normal saline, intraperitoneally (i.p.), was approved every other day

(14) Fluid shear stress induces cell migration and invasion via activating autophagy in HepG2 cellsCell adhesion & migrationDecember 1, 2019Yan Z, Su G, Gao W, He J, Shen Y, Zeng Y, Liu X.inhibitor application, HepG2 cells were pretreated with 0.5 µM integrin inhibitor Cliengitide (Cli, HY-16141, MedChemExpress, USA) for 6 h, 10 µM microfilament polymerization inhibitor Latrunculin B (LaB, ab144291,

(15) A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding IntegrinsScientific reportsJanuary 11, 2017Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, Reuning U, Notni J, Wester HJ, Mas-Moruno C, et al.

(16) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumorsAnnals of oncology : official journal of the European Society for Medical OncologyAugust 1, 2007Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, et al.

(17) Disturbances in voluntary recruitment order of low and high frequency motor units on blockades of proprioceptive afferent activityActa physiologica ScandinavicaFebruary 1, 1976Grimby L, Hannerz J.

Be the First to Write a Review!

Cilengitide from MedChemExpress

Description

MedChemExpress

Citations (17)

Reviews

Cilengitide from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map